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Abstract The objective of the study is to examine the impact
of gout and its treatments on health-related quality of life
(HRQOL) using focus group interviews. From the baseline
phase of a cohort study of HRQOL in gout, 17 participants
(15 males, mean age 71 years) with varying attack frequency
and treatment with and without allopurinol participated in one
of four focus group interviews. All interviews were audio-
recorded and transcribed verbatim. Data was analysed themat-
ically. Physical and psychosocial HRQOL in gout was affect-
ed by characteristics of acute gout (particularly the unpredict-
able nature of attacks, location of joint involved in an attack,
pain and modifications in lifestyle), lack of understanding of
gout by others (association with unhealthy lifestyle, symp-
toms ridiculed as non-severe and non-serious) as well as par-
ticipants (not considered a disease) and the lack of information
provided by physicians (about causes and pharmacological as
well as non-pharmacological treatments of gout). Participants
emphasised the impact of acute attacks of gout and prioritised
dietary modifications and treatment of acute attacks over long-
term urate-lowering therapy. Characteristics of acute gout,
lack of understanding and information about gout and its treat-
ments perpetuate poor HRQOL. HRQOL (maintenance of
usual diet and reduced frequency of attacks) was associated
with urate-lowering treatment. Better patient, public and prac-
titioner education about gout being a chronic condition asso-
ciated with co-morbidities and poor HRQOL may improve
understanding and long-term treatment of gout.
Keywords Focus group interviews . Gout . Health-related
quality of life . Primary care . Qualitative study . Thematic
analysis
Introduction
Gout is the commonest inflammatory arthritis, affecting 2.5 %
of the UK population [1] and causes attacks of acute gouty
arthritis, joint damage and chronic pain. It is associated with
co-morbidities (obesity, hypertension, diabetes, ischaemic
heart disease, chronic kidney disease and treatment with di-
uretics) [2, 3] and socio-demographic features (older age,
male gender, ethnicity and lower socio-economic status)
[4–6]. Given the complex links between gout, co-morbidities
and socio-demographic characteristics, health-related quality
of life (HRQOL) in gout is likely to be associated with all
these patient characteristics. HRQOL is defined as: BThe value
assigned to the duration of life as modified by impairments,
functional states, perceptions and social opportunities that
are influenced by disease, injury, treatment or policy^ [7].
To date, qualitative studies of gout have explored HRQOL
but have focused on the knowledge and beliefs of patients and
providers and perceived barriers to effective treatment rather
than on the impact of gout and its treatment on quality of life
[8–13]. These studies were conducted using one-to-one inter-
views with patients [10, 12] in mixed primary and secondary
care settings [9]. One secondary care-based study used nom-
inal group interviews to assess the impact of gout on HRQOL
but focused on the influence of gender and race on HRQOL
[8]. To our knowledge, this is the first primary care-based
qualitative study to explore patients’ perspectives on how gout
and its treatments affect HRQOL, using focus group
interviews.
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Methods
Participants for this study were recruited from the baseline
phase of a primary care-based cohort study of HRQOL in gout
[14]. A sub-sample of 120 baseline responders with a primary
care Read code diagnosis of gout or prescription of colchicine
or allopurinol in the preceding 2 years were invited to partic-
ipate in focus group interviews. Drawing on the expertise of
the research team, a purposive sampling framework was de-
veloped to include participants whose experiences
encompassed a range of frequency of attacks over the last
12 months and a proportion taking allopurinol. Since
febuxostat is used infrequently in UK primary care, interview
participants were not purposively sampled according to
febuxostat use.
Non-responders were sent a reminder invitation letter after
2 weeks: Those who did not reply to the reminder letter were
not contacted again. Forty-two potential participants who
agreed to take part in the interviews were telephoned by the
researcher to arrange an interview. Nineteen of these 42 con-
firmed ability to attend one of the four allocated interview
dates. Two did not attend due to unforeseen circumstances,
leaving 17 participants. Each of the four focus groups had
between three and five participants. Details of the recruitment
process are illustrated in Fig. 1.
Prior to commencing the interview, the procedures outlined
in the participant information sheet were discussed with each
participant. Participants were given the opportunity to ask
questions. Written informed consent to take part in the study
(including the use of quotations) was obtained from all partic-
ipants and confirmed at the end of the interview. Three group
interviews were held at Keele University and one at a general
practice. Ethical approval was gained from the North West
Liverpool East Local Research Ethics Committee (REC refer-
ence number 12/NW/0297).
Focus groups rely on the interaction between group partic-
ipants to generate novel ideas and promote discussion around
the emerging topics [15]. The moderator (PC) used a topic
guide to guide the interview, which had been developed in
conjunction with five expert patients with gout from the re-
search centre’s Research Users Group. The topic guide was
pre-determined but not prescriptive, and participants were en-
couraged to lead the discussion. The main question of the
focus group enquiry was: BWhat impact has gout and its treat-
ment had on your Quality of Life?^All interviews were audio-
recorded and transcribed verbatim.
Thematic analysis
Thematic analysis was based on Braun and Clarke’s frame-
work [16], modified by combining reviewing and defining
themes into one stage:
I. Familiarisation with the data set
II. Generating and clustering codes together
III. Identification of themes
IV. Review and definition of themes
V. Production of the report
The original transcripts were scrutinised by three re-
searchers (PC, JR, JL) for data relevant to the impact of
gout (and its treatments) on all aspects of quality of life,
which were then coded. Codes identified by the three re-
searchers were largely similar, and any differences were
discussed until a consensus was reached. Codes used to
annotate the main text that were similar in nature were
clustered together into themes. Similar themes were
organised under one overarching theme or higher order
descriptive label. Thematic analysis was data driven
(inductive) as far as possible; however, previous clinical
experience may inevitably have contributed to some degree
of deductive analysis. Data analysis and interpretation were
iterative as new themes developed on repeated readings of
the transcripts, until no new themes could be identified
(theoretical saturation) [10].
Fig. 1 Recruitment process for the qualitative focus group
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Results
Seventeen people participated in the interviews (mean age
71 years, 15 males). One participant accompanied another
participant with gout (for whom she was a carer) but did not
have gout herself. Participant characteristics are presented in
Table 1.
Three overarching themes were developed: characteristics
of gout, understanding of gout and beliefs about treatment of
gout amongst the participants. The impact of gout on HRQOL
is outlined through these themes and sub-themes presented
below, illustrated with relevant quotations from the transcripts
(Tables 2, 3 and 4).
Characteristics of gout
The physical and psychological impact of gout attacks
Participants reported pain affecting multiple sites in the body
and varying in intensity (see Table 2). The duration of severe
pain could last as long as 3 weeks, but some participants
reported a low intensity of pain lasting almost a decade. Des-
peration to relieve the severe pain of gout was also apparent
from some of the extreme self-management techniques). An-
ticipated worsening of pain upon contact of the affected body
part with another person or object in bed reduced comfort and
the quality of sleep. Gout was perceived to be more severe if
pain was located in larger joints during an attack compared to
smaller joints (Table 2) and considered more painful than a
fractured bone. Gout caused isolation through reduced mobil-
ity arising from pain and swelling in the joints. Being immo-
bile, housebound and unable to do things led to feelings of
boredom.
Unpredictable nature of attacks
The unpredictable onset of acute attacks led to difficulties in
planning activities or social engagements in the future, illus-
trating the direct impact of gout on HRQOL in terms of social
opportunities. Some participants were reluctant to make com-
mitments which might not be fulfilled in the event of a sudden
attack. Fear of recurrent and unpredictable attacks of gout led
one participant to start treatment with allopurinol, which he
would not have considered otherwise (Table 2).
Modification of environment and lifestyle
Symptoms of gout caused hindrance in performing activities
of daily living which meant that participants made modifica-
tions in their lifestyle, place of living and work environment.
Gout not only limited the lifestyles and hence HRQOL of
participants affected by it but also of the family member
(carer) who reported feeling unhappy or guilty enjoying activ-
ities without the person with gout (Table 2).
Understanding of gout
Over-indulgence as a cause for gout and dietary
modifications
Although some participants considered dietary modifications
a key to preventing recurrent attacks (particularly if they
thought their previous dietary habits had been ‘overindul-
gent’), others reported uncertainty regarding diet and its role
in causing and treating gout. There was a lack of information
from ‘trusted’ sources such as health care practitioners, and
participants relied upon both National Health Service (NHS)
endorsed and unendorsed websites for detailed dietary infor-
mation. Self-discovered sources of information were consid-
ered to be overwhelming and frightening (Table 3). Partici-
pants also reported lack of enjoyment of previously enjoyed
activities associated with extremely restricted dietary life-
styles. This aspect of HRQOL is an important one and, at
the same time, a confusing one for people with gout.
Gout not a disease
The stigma associated with stereotypical ideas of gout affect-
ing those who led an unhealthy lifestyle (high consumption of
Table 1 Participant characteristics
Gender Age
(years)
Interview
location
GP/Keele
Number of
attacks in last
12 months
Taking
allopurinol
F 76 GP 5 Yes
M 75 Keele 5 No
M 73 GP 2 No
M 55 Keele 3 Yes
M 67 Keele 1 No
M 68 Keele 3 Yes
M 85 Keele 3 No
M 77 Keele 2 Yes
M 72 GP 2 Yes
M 81 Keele 3 Yes
M 68 Keele 2 Yes
M 64 Keele 2 No
M 64 Keele 2 Yes
M 78 Keele 3 Yes
M 60 Keele 4 No
M 63 Keele 3 Yes
M 75 Keele 5 No
F Unknown Keele NA NA
M male, F female, GP general practitioner, NA not applicable
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meat and alcohol) was still widely prevalent in society accord-
ing to participants. However, some participants did not con-
sider personal actions such as lifestyle choices to be a key
cause of gout as they saw it as an illness resulting from a
‘natural’ accumulation of metabolites in the body rather than
a disease. Often, symptoms of gout (joint aches and pains)
were attributed by participants to part of a ‘normal’ ageing
process, leading to dismissal of the diagnosis.
Gout considered humorous and only understood by close
contacts
Participants considered gout to be a serious and extremely
painful condition and were angered by others not taking it
seriously. Participants felt that the rapid onset of symptoms,
and others’ understanding of it as a non-fatal condition, meant
that there was disbelief of the severity of symptoms and the
condition. Perceived lower priority for research into gout
(compared to other conditions such as drug misuse or
dependency which were viewed as self-inflicted) was consid-
ered synonymous with the lower severity assigned to it by
health care practitioners (Table 3). Awareness and understand-
ing of gout were considered better amongst family and friends
who realised the severity of symptoms after being involved in
the care or observation of someone who had gout. The per-
ceptions of other people can be seen to have an impact on
patients’ HRQOL.
Lack of information from health care practitioners
Lack of information prompted participants to conduct their
own internet searches on causes and treatments of gout. They
were, however, concerned about the quality and authenticity
of information available via these internet sources. Partici-
pants felt that health care practitioners assumed that their gout
was due to excessive consumption of alcohol (Table 3),
Table 2 Participant quotations to illustrate the impact of gout characteristics on HRQOL
Higher order theme Sub-theme Quotations within transcripts
Gout characteristics The impact of gout attacks I mean a toe is relatively innocuous, if you’ve got it in your knees or hips or something,
then yeah, it’s a little more worrying
So I can’t really go anywhere or do anything in that sense
You’re so bored sat there not being able to move your foot, [laughter] that you get
psychological side effects.
I’ll get into freezing cold water and sit there. [yeah] I take that pain to take that off
You can’t turn over, when you’re half asleep, you accidently touch something.
You’re frightened that she’s going to touch it
But mine lies all over my body, everywhere. From one to another. [right] All down
one side, well everywhere
You really bang your head against the wall
It gets that painful I’ll cry. I can’t get rid of it.
If it breaks, [yeah] you go to the hospital, put it in plaster, and you’re—a bit of a throbbing
and it’s gone, but with gout it’s bang, bang, bang for days and days
Unpredictable nature of attacks The only reason that erm I went back this time to—to see about it was the fact that I was a
little bit frightened if I was going to go on holiday the next day it was going to clobber
me that day
It’s the unpredictability of it, you know, you make a plan to, I don’t know, maybe go to
theatre in five weeks’ time and when it gets closer you think god, I hope I don’t get gout
just the night before
Lifestyle modification Well I couldn’t get my shoe on, last—a week ago since my last one
When I found out it was gout I changed my lifestyle and stopped drinking
I have cherries. And I have seeds sometimes, celery seeds
Because the damp weather, the cold and damp weather, is just not helping him at all.
And they moved, they sold up and they moved to warmer climates
I stopped doing these high impact erm exercises, I stopped long distance walking,
because it was painful
Like it’s office work now, like you know a desk job now
Well we can’t go out and do the same things
I could go out and leave him. [right, yeah] But there’s no way I would. [okay] So it does
have an effect on the whole unit
I’m a long distance runner, so when I can’t run like I hate it.
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leading to a reported lack of rapport between health care prac-
titioners and patients.
Beliefs about treatment of gout
Lack of contact with health care practitioner
Self-treatment of acute attacks of gout with non-
pharmacological methods was reported by participants.
Obtaining topical or oral non-steroidal anti-inflammatory
drugs (NSAIDs) from the pharmacy was preferred by
some participants to presentation to the general pactitioner
(GP) for treatment. Some confessed to treating recurrent
attacks with left over NSAIDs (obtained originally from a
previous consultation). Participants complained of the un-
availability of appointments at their GP surgery and the
spontaneous resolution of symptoms by the time they
were seen. Lack of presentation to the GP for recurrent
attacks may lead to lack of opportunity to understand and
address the long- term consequences of chronic
Table 3 Participant quotations to illustrate the impact of understanding of gout on HRQOL
Higher order theme Sub-theme Quotations within transcripts
Understanding of gout Over-indulgence and dietary
modifications
Yeah I know I kind of guess when I might be getting one, [yeah] by the fact that
I’ve over indulged somewhere.
Oh they put everything on there. What am I going to eat? You have to take it with
a pinch of salt.
When I looked onto NHS Direct, after I’d got it, that frightens the life out of you
if you do anything because you get five pages
It’s just a great muddle about when it comes to food
Give them a 12-month diary or something like that. [right] And write each day
what they’ve done that day. [okay] What they’ve drunk that day. What they’ve
eaten that day. [yeah] And do a research programme like that and maybe you
could come up with some facts
Gout not a disease but natural For me, disease is something like malaria and erm… But it isn’t is it, it’s just a
build-up of stuff that’s naturally in your body
I suppose I was a bit in self-denial, I don’t suffer from gout
There’s more people than what we think who get it a bit, not coming forward and
saying this is a bigger serious problem
In fact I would put it down to aches and pains getting aged really rather than anything
Gout considered humorous by
others and only understood
by close family and friends
I think there’s certain diseases that are quite humorous to—and they’re not, but they’re
humorous to everybody else who hasn’t got them
You don’t brag about it do you?
Straightaway it’s with the well-off people and [that’s right, yeah] and the rich food.
It’s this thing erm…they don’t realise what it is and they just use the old wives’ tale,
the port and pheasant, rich living
It happens so quick, people just don’t believe it.
When you’ve got gout your partner or friend or whatever, if they see you with gout
when it’s bad, they suddenly realise how bad it is
I don’t think it’s perceived to be life threatening, whereas cancer and heart attacks are
They should spend more money on stuff which we ain’t brought this on ourselves,
[yeah] it’s because it’s an illness, it’s—whatever it is, we’ve got with us, whereas
drugs and—they’ll spend money
Lack of information from health
care practitioner
I found out for myself basically. [okay] So the doctor didn’t really explain it that well
We’ve all got ignorance of it. Doctors don’t sort of explain exactly what it is
I’d like to know the side effects though, properly [yeah] from a doctor, and not from
the internet
No, you go in, you go in, you’re the doctor, how much do you drink? I said I don’t
drink doctor. But as I say it’s still treated as a bit of a thing, you know. I think
doctors do actually. You know, you’ve been drinking. How much do you drink?
BI would say my GP almost dismissed my view that [yeah] the attacks were brought
on when I stressed the joint, but on the NHS site, definitely it states [yeah] that
if you stress a joint it can instigate the gout^
BBut you couldn’t talk to my doctor about it, he wasn’t interested^
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progressive gout and its associated co-morbidities on
HRQOL for the patient.
Reluctance to prescribe and take allopurinol
A recurrent theme in the interviews was that lifelong urate-
lowering therapy (ULT) treatment with allopurinol was not
widely advocated by health care practitioners if the patients
had single or infrequent attacks or in the presence of co-
existing renal impairment. Instead, treatment of acute attacks
only with NSAIDs was often reportedly advised by health
care practitioners, as well as being the preferred approach
for some participants (see Table 4). Those who had mild
symptoms were content without any treatment at all or quick
resolution of symptoms with NSAIDs. Reluctance to take
lifelong treatment (allopurinol) was expressed by a few par-
ticipants despite having no particular concerns regarding allo-
purinol. These participants may consider taking lifelong med-
ication a burden. Some participants reported being less con-
cerned about taking allopurinol for the remainder of their lives
as they grew older (Table 4). Not taking treatment can have a
negative effect on HRQOL.
Concerns about side effects of treatment
Lack of information about the possibility of an acute attack
due to allopurinol initiation or titration caused concerns for
some participants. Other participants were informed of this
possibility but were incorrectly advised to discontinue
treatment with allopurinol should an acute attack occur.
Some participants (including the carer) were worried about
interaction between allopurinol and other medications tak-
en for co-morbid conditions. Treatment of gout with allo-
purinol was considerably harder in the presence of other
co-morbid conditions such as renal disease, according to
some participants.
Perceived benefits of treatment
Some participants wished for earlier treatment with allopuri-
nol once they realised that treatment could reduce the frequen-
cy of attacks (Table 4). Treatment with allopurinol was per-
ceived to improve HRQOL by reducing the frequency of re-
current attacks.
Table 4 Participant quotations to illustrate the impact of treatments on HRQOL
Higher order theme Sub-theme Quotations within transcripts
Lack of contact with HCP A female participant reported that her general practitioner (GP) was reluctant to refer her to a
specialist even when her gout was sub-optimally controlled
Treatment Have a supply if I can feel it coming on, because I’ve got a spare box at home
I dropped it down myself to one a day, I don’t know what the doctor will say when I tell him
So it takes three, like it can take five days to see my doctor. You know, so by the time I get
in there it’ll probably have eased down a lot
Reluctance to prescribe
and take allopurinol
He says I wouldn’t really recommend it if you can get away with it, just come in if you start
getting an attack
I find it quite manageable with anti-inflammatory tablets I take for it
I said I’m not being funny here but can I have this one please because this one seems to be
the new one, and much better. She didn’t offer it because it’s obviously more expensive
I’m old enough now that another tablet for the rest of my life doesn’t make a lot of difference
I find mine just goes quickly, so I’m tremendously happy, I wouldn’t want to be on long term
Allopurinol, not because there’s anything wrong with it, or anything, or anything else,
I’m very, very content with what I’ve got
Concerns about side
effects of treatment
Because of the other medication that he takes, the gout tablets don’t sit well
My kidney function, he always checks because I think it’s on the border line, so I think that
might have been one of the reasons he was a little bit wary about erm prescribing Allopurinol
And then you go—and then you get gout, it gives you gout.
My medic said that Allopurinol can actually cause gout to flare up again. If I had any problems,
any pain, [yeah] to stop taking it immediately.
Benefits of treatment You go two for I think it’s two months, I’ve forgotten now, [yes] and then you go to three,
and then that is—that’s a miracle
Go to the doctors and get the pills… I wish he’d done it two years ago
BWell I’m still eating mussels and king prawns and everything like that. The Allopurinol
I suppose is to let you do that isn’t it?^
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Discussion
The impact of gout and its treatments on broad physical, social
functioning and mental health [17] components of HRQOL
was represented through three higher order themes: gout char-
acteristics, understanding of gout and treatments for gout. The
effect on physical HRQOL was evident through its character-
istic symptoms of pain and swelling in the affected joint, lead-
ing to reduced mobility and potential adverse effect on psy-
chological HRQOL. Social HRQOL may be affected by the
unpredictable nature of attacks and modifications in lifestyle.
Participants’ treatment preferences and lack of knowledge
about the benefits of ULT may contribute towards poor
HRQOL in gout.
The impact of gout symptoms on physical functioning and
psychological HRQOL [8, 10], work absence and productiv-
ity has been described previously [18]. Under-reporting of
gout due to reluctance in accepting the diagnosis (stigma at-
tached with the stereotypical phenotype of those who get
gout) and stoicism due to societal perceptions (non-serious)
have also been found previously [10]. Non-presentation to a
health care practitioner for treatment of further attacks pre-
vents the opportunity to discuss the association of gout with
permanent joint damage, disability and co-morbidities [19]
and may lead to poor HRQOL, which can be addressed
through treatment with a urate-lowering agent such as allopu-
rinol. A previous observational cohort study has shown statis-
tically and clinically meaningful improvement in HRQOL
(through reduction in serum uric acid (SUA) and the frequen-
cy of attacks) in participants with chronic gout treated with
ULT [ 20]. Participants in our study highlighted lack of aware-
ness of the need for lifelong ULT, concerns about side effects,
induction of acute attacks with ULT, concerns regarding
polypharmacy causing adverse drug interactions and percep-
tion that treatment is only needed for acute attacks as reasons
for not taking ULT, which have been common to other qual-
itative studies using semi-structured or nominal group inter-
views [9, 12, 13]. Such beliefs may contribute towards under-
utilisation of ULT in primary care [21]. Leaving recurrent
attacks untreated may lead to progressive gout which has been
previously associated with negative experiences [10]. Co-
morbidities such as renal impairment have been independently
associated with poor HRQOL [22]. Better psychological
HRQOL (measured by the Short Form 36 scale) in adults
>70 years of age with treatment failure gout compared to
younger subjects and general population has been seen previ-
ously [23].
One important concept identified in this study is the dis-
tinction between gout as an illness (social meaning of the
condition) rather than a disease (a biological condition) [24].
This belief may be rooted within social constructionism (ill-
nesses are socially constructed at an experiential level which is
based upon the individual’s understanding of the disease and
perceptions of his or her identity post diagnosis) [25]. Another
addition to the findings of existing studies is that participants
in this study considered the unpredictable nature of attacks
and location of joint pain and swelling to be of utmost impor-
tance in affecting their HRQOL. These findings may explain
how previously noted features of quantitative studies [26, 27]
such as attack frequency and number of joints involved during
an attack affect HRQOL. Although well-recognised as fea-
tures of gout by health care practitioners, associated co-
morbidities [28] and tophi were noticeably not discussed
amongst participants of this study, which may imply that they
did not consider these to affect HRQOL. Although some par-
ticipants acknowledged that treatment of gout was difficult in
the context of co‐morbidities such as renal diseases, none
attributed co‐morbid conditions as a risk factor for
hyperuricaemia and gout. Untreated co-morbid conditions in
gout may impair HRQOL independent of gout factors [22].
Tophi have also been associated with poor HRQOL (mea-
sured by generic questionnaires) in other studies [27, 29]. This
may be due to the fact that tophi are less common in primary
care, where our sample was taken from, compared to second-
ary care, where much previous research has been conducted.
Other findings of our study supported by existing literature
include the desire for greater health care practitioner-led infor-
mation [9] and the emphasis on diet as a key causative factor
in development of gout [13, 30]. However, whereas partici-
pants in our study were keen on modifying their lifestyle to
prevent recurrent attacks, participants in the other study [30]
did not perceive gout to be influenced by their personal ac-
tions. Such differences in findings may be attributed to the
sampling frame (participants with disease duration <10 years),
geographical location (NewZealand) and study design (cohort
study conducted using the Brief Illness Perception
Questionnaire).
Strengths of the study
To our knowledge, this is the first focus group study to eval-
uate the effects of gout and its treatment on HRQOL. Focus
group interaction between participants may have contributed
towards uninhibited discussion [31]. Group interaction also
promoted exchange of ideas, anecdotes and information,
which may have led to novel themes that would not have
developed in a one-to-one setting. Such themes add depth to
our understanding of the impact of gout. Although initially
designed to study the impact of gout and its treatment on
HRQOL, the group interactions went beyond these realms
and introduced discussions about beliefs and knowledge of
gout, both of which link into the impact on HRQOL. The
patient sample was broadly representative of the experience
of the primary care population with gout in the UK as it cov-
ered a range of attack frequencies and just over half of the
participants were onULT (allopurinol). Participation of a carer
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for someone with gout added a first-hand perspective of the
impact of gout on family and friends. Independent reviews of
the transcripts by three researchers added robustness to the
identification of the codes, ensuring that they reflected partic-
ipants’ views as closely as possible.
Limitations of the study
Limitations of this study include a sample consisting of exclu-
sively Caucasian and mostly male participants, reducing the
applicability of the findings beyond these ethnic and gender
groups. However, data from qualitative research is useful in
enhancing understanding of the social phenomenon through
volume, depth and complexity [31]. Previous qualitative stud-
ies have examined the impact of gender and race on HRQOL
in people with gout but have not explored the influence of age
[8, 13]. Owing to the study design and sample, we were un-
able to examine this aspect of HRQOL in gout which should
be the focus of future research studies. Although largely pres-
ent in a passive role, the presence of a moderator and research
assistant may have influenced the participant responses.
Implications for clinical practice and further research
From the participants’ perspective, HRQOL is very much in-
fluenced by the acute symptoms and ‘unpredictable’ nature of
gout. However, patients need to bemade aware of the irrevers-
ible joint damage (regardless of joint location and size) asso-
ciated with untreated chronic gout [32] which may lead to
chronic poor HRQOL over time. At present, there appears to
be patient preference for short-term symptomatic treatment of
gout over ULT. Health care practitioners need to be aware and
be able to explain to patients that ULT is necessary to see a
long-term reduction in SUA thereby reducing the frequency of
attacks, shrinkage and dissolution of tophi [33], leading to an
improvement in HRQOL long term [20]. As well as the pos-
sibility of onset of an acute attack of gout, they should be
advised about its management and the need to continue allo-
purinol through the duration of the acute attack.
Patients also need to be made aware by health care physi-
cians that gout is a recognised independent risk factor for co-
morbidities [34–36] which should be screened for and treated
alongside gout as they are known to be independently associ-
ated with poor HRQOL [22]. Greater awareness of gout in the
context of co-morbidities and genetic susceptibility [37] may
steer away from the historical association of gout with exces-
sive intake of alcohol and food [2, 32]. Greater information on
the role of diet and exercise from health care practitioners
could also promote lifestyle modification and patient engage-
ment in management of the condition.
The influence of gender (females) and cultural perceptions
or beliefs (different ethnicities) on HRQOL could also be ex-
plored through further qualitative studies. Although lack of
information from clinicians was a recurrent theme, this was
the participants’ perception and it may be useful to explore
clinicians’ perspective on this issue as well as their percep-
tions of what affects HRQOL in gout.
Key messages
& HRQOL was impaired due to gout characteristics, lack of
understanding and information about gout.
& Patients expressed a general preference for treatment of
acute attacks of gout over lifelong ULT.
& Better patient (and physician) education is warranted to
address these factors which perpetuate poor HRQOL.
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